Compare Enveric Biosciences Inc (ENVB) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs KLA Corp. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while KLA Corp. trades at $200.45 (market cap $256.86B). The key difference: KLA Corp. is far larger — about 38394.6× Enveric Biosciences Inc's market cap, and KLA Corp. pays a 0.47% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and KLA Corp. for 60 Days on average.
| ENVB | KLAC | |
|---|---|---|
Market Cap | $6.69M | $256.86B |
Volume | 41,141 | 7,016,455 |
Sector | Health | Technology |
52-Week High | $10.80 | $301.71 |
52-Week Low | $1.27 | $98.28 |
Typical Hold Time | 14 Days | 60 Days |
Enterprise Value | -$1.60M | $258.11B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
KLA Corporation (KLAC) trades at $196.72, down 0.37% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported revenue of $12.16 billion in 2025, with net income of $4.06 billion and a robust net margin of 33.41%. Recent earnings beats and a significant backlog driven by AI demand highlight operational strength, while analyst consensus remains strongly positive with a $223.88 price target.
The outlook for KLAC is favorable, supported by AI-led growth in semiconductor equipment demand and solid financials, though high valuation multiples and competitive pressures pose risks. Upside potential exists if the company continues to exceed earnings expectations and capitalize on industry tailwinds, but investors should monitor margin trends and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
